(Q43715277)

26 November 2017

title

(-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release (English)

1 reference

26 November 2017

Shimazu S

1

1 reference

26 November 2017

Takahata K

2

1 reference

26 November 2017

Katsuki H

3

1 reference

26 November 2017

Tsunekawa H

4

1 reference

26 November 2017

Tanigawa A

5

1 reference

26 November 2017

Yoneda F

6

1 reference

26 November 2017

Knoll J

7

1 reference

26 November 2017

Akaike A

8

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

European Journal of Pharmacology

26 November 2017

published in

1 reference

26 November 2017

volume

421

1 reference

26 November 2017

issue

3

1 reference

26 November 2017

page(s)

181-189

1 reference

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Treatment of parkinsonism with bromocriptine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

A comparison of circling models for the detection of antiparkinson activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

The Neurobiological Substrates of Depression in Parkinson’s Disease: A Hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Amphetamine-induced locomotor stereotypy in rats is reduced by a D1 but not a D2 antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Locomotor stereotypy produced by dexbenzetimide and scopolamine is reduced by SKF 83566, not sulpiride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Long-term sensitization of apomorphine-induced rotation behavior in rats with dopamine deafferentation or excitotoxin lesions of the striatum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

(-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Dopamine receptor supersensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Strain differences to the effects of central acting drugs on Sidman avoidance response in Wistar and Fischer 344 rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Amantadine in the Treatment of Parkinson's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Dopamine: Release from the Brain in vivo by Amantadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2801%2901040-8

10.1016/S0014-2999(01)01040-8

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference